Diabetes Mellitus
Conditions
Brief summary
Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM) System
Detailed description
The objective of the study is to establish performance of the Dexcom CGM System (System) in comparison to a blood glucose comparator method.
Interventions
Continuous Glucose Monitoring System
Sponsors
Study design
Masking description
All systems worn will be blinded. Sensor wear locations will be pre-assigned. All sensor insertions will be performed at the clinic by study staff.
Eligibility
Inclusion criteria
* Ages 2 or older * Diagnosis of Type 1 diabetes or Type 2 diabetes * Willing to wear the required number of Systems for the total duration of study wear * Willing to participate in Clinic Session(s) during study wear
Exclusion criteria
* Presence of extensive skin changes/diseases at sensor wear site(s) that preclude wearing the sensor(s) on skin * Known allergy to medical-grade adhesives * Pregnancy * Hematocrit outside specification * ≥ 18 years of age: * Male: 36.0%; * Female: 33.0%; * 13-17 years of age: 35.0%; * 7 years - 12 years of age: 32.0%; * End stage renal disease and currently managed by dialysis or anticipating initiating dialysis during the study wear period * Required or scheduled to have a Magnetic Resonance Imaging (MRI) scan, Computed Tomography (CT) scan, or diathermy during the study wear period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| System Performance | 10 days | System Performance will be characterized with respect to comparator venous plasma measurements. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| System Related Adverse Device Effects | 10 days | System will be characterized by Adverse Device Effects experienced by study participants |
Countries
United States